Dopamine
Adrenergic and Dopaminergic Agents
Sold as NEOATRICON
- Drug class
- Adrenergic and Dopaminergic Agents
- Availability
- Prescription only
- Routes
- Intravenous
- Markets covered
- 2
- Products on record
- 12
Overview
Plain-language summary, compiled from the cited regulatory records
Dopamine is an adrenergic and dopaminergic agent [1]. It is approved to improve hemodynamic status in patients experiencing distributive shock or shock resulting from reduced cardiac output [1]. Dopamine hydrochloride in dextrose injection is a catecholamine used for this purpose [1].
This medication is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 9 | May 29, 2026 |
| US United States | FDA | 3 | May 12, 2026 |
GBUnited Kingdom· MHRA
9 products
Uses
Dopamine is indicated in adults for the correction of haemodynamic imbalance present in: 1) Acute hypotension or shock associated with myocardial infarction, endotoxic septicaemia, trauma and renal failure. 2) As an adjunct after open heart surgery where there is persistent hypotension after correction of hypovolaemia.
3) In chronic cardiac decompensation as in congestive failure.
How to take
USUnited States· FDA
3 products
Uses
1 INDICATIONS AND USAGE Dopamine Hydrochloride in Dextrose Injection is indicated to improve hemodynamic status in patients in distributive shock, or shock due to reduced cardiac output. Dopamine HCl in Dextrose Injection is a catecholamine indicated to improve hemodynamic status in patients in shock.
( 1 )
How to take
Drug interactions
Known interactions involving Dopamine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL294720004 · revised March 13, 2026
- [2]FDA DailyMed · 08f23f6e-150d-45… · revised May 12, 2026 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.